ETRAElectra Therapeutics, Inc.
13.92USD+3.11%Mkt Cap: 850.52M $P/E: —1d ago
Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, EL…
Industry Peers
Biotechnology$128.84BUSDP/E 29.6
$80.80BUSDP/E 19.4
$69.04BUSD
$58.67BUSDP/E 37.9
$61.45BUSDP/E 37.7
$43.96BUSDP/E 18.7
$40.93BUSD
$39.69BUSDP/E 62.9
$33.75BUSDP/E 31.4
$32.69BUSDP/E 42.5
$28.73BUSD
$26.42BUSD
$25.27BUSDP/E 15.9
$24.62BUSD
$21.33BUSDP/E 27.5
$20.24BUSDP/E 27.4
$15.67BUSDP/E 16.5
$15.63BUSDP/E 18.5
$14.24BUSD
$14.18BUSDP/E 18.0
Key Statistics
Company
Market Cap850.52M $
Enterprise Value1.03B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-61.98M $
Revenue/Share—
Last Price13.92 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees46
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B—
EPS (TTM)-2.65
EPS (Forward)—
52W Range
13.3128% of range15.50
52W High15.50 USD
52W Low13.31 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE37.92%
ROA-62.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-60.48M $
CapEx (TTM)733.00K $
FCF Margin—
FCF Yield—
Net Debt-95.74M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.01
Current Ratio7.37
Quick Ratio7.19
Book Value/Sh—
Cash/Share1.599 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.61.10M
Float61.10M
Insiders—
Institutions—
Technical
SMA 5013.50 (+3.1%)
SMA 20013.50 (+3.1%)
Beta—
S&P 52W Chg14.29%
Avg Vol (30d)2.97M
Avg Vol (10d)5.12M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—